Caspase recruitment domains. New potential markers for diagnosis of hepatocellular carcinoma associated with HCV in Egyptian patients

Zekri, Abdel-Rahman N.; El-Kassas, Mohamed; Saad, Yasmin; Bahnassy, Abeer A.; El-Din, Hany Khatab Sameh Seif; Darweesh, Samar K; Hafez, Hassan A.; Esmat, Gamal

doi:10.1016/s1665-2681(19)31319-5

Cited by 10 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, these molecules might represent novel therapeutic targets. Namely, CARD9 is a marker of tumor progression and poor prognosis in hepatocarcinoma (HCC), B cell lymphoma, and clear cell renal carcinoma [ 40 – 42 ] and promotes metastatization activating metastasis-associated macrophages (MAM) [ 43 ]. Besides, the higher expression of FANCG suggested that REC tumors displayed increased DNA damage and activated DNA repair.…”

Section: Discussionmentioning

confidence: 99%

Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma

et al. 2018

View full text Add to dashboard Cite

BackgroundEffective target therapies for intrahepatic cholangiocarcinoma (ICC) have not been identified so far. One of the reasons may be the genetic evolution from primary (PR) to recurrent (REC) tumors. We aim to identify peculiar characteristics and to select potential targets specific for recurrent tumors.Eighteen ICC paired PR and REC tumors were collected from 5 Italian Centers. Eleven pairs were analyzed for gene expression profiling and 16 for mutational status of IDH1. For one pair, deep mutational analysis by Next Generation Sequencing was also carried out. An independent cohort of patients was used for validation.ResultsTwo class-paired comparison yielded 315 differentially expressed genes between REC and PR tumors. Up-regulated genes in RECs are involved in RNA/DNA processing, cell cycle, epithelial to mesenchymal transition (EMT), resistance to apoptosis, and cytoskeleton remodeling. Down-regulated genes participate to epithelial cell differentiation, proteolysis, apoptotic, immune response, and inflammatory processes. A 24 gene signature is able to discriminate RECs from PRs in an independent cohort; FANCG is statistically associated with survival in the chol-TCGA dataset. IDH1 was mutated in the RECs of five patients; 4 of them displayed the mutation only in RECs. Deep sequencing performed in one patient confirmed the IDH1 mutation in REC.ConclusionsRECs are enriched for genes involved in EMT, resistance to apoptosis, and cytoskeleton remodeling. Key players of these pathways might be considered druggable targets in RECs. IDH1 is mutated in 30% of RECs, becoming both a marker of progression and a target for therapy.Electronic supplementary materialThe online version of this article (10.1186/s12864-018-4829-0) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Thus, CARD9 deficiency inhibits liver metastasis of colon carcinoma with decreased number of M2 macrophages (CD45 + F4/80 + CD206 + ) ( 140 ). Increased level of CARD9 mRNA is also observed in hepatocellular carcinoma via liver biopsies ( 40 ). There may be a sex difference in the role of CARD9 in tumor biology.…”

Section: Card9 and Diseasesmentioning

confidence: 99%

CARD9 Signaling, Inflammation, and Diseases

et al. 2022

View full text Add to dashboard Cite

Caspase-recruitment domain 9 (CARD9) protein is expressed in many cells especially in immune cells, and is critically involved in the function of the innate and adaptive immune systems through extensive interactions between CARD9 and other signaling molecules including NF-κB and MAPK. CARD9-mediated signaling plays a central role in regulating inflammatory responses and oxidative stress through the productions of important cytokines and chemokines. Abnormalities of CARD9 and CARD9 signaling or CARD9 mutations or polymorphism are associated with a variety of pathological conditions including infections, inflammation, and autoimmune disorders. This review focuses on the function of CARD9 and CARD9-mediated signaling pathways, as well as interactions with other important signaling molecules in different cell types and the relations to specific disease conditions including inflammatory diseases, infections, tumorigenesis, and cardiovascular pathologies.

show abstract

“…Additionally, CARD9 has been suggested to be used to diagnose tumors. Zekri et al (2013) studied 130 patients with hepatitis C virus (HCV)-associated liver disease, 40 of whom were diagnosed with HCC. The results showed that the expression level of CARD9 in HCC was significantly higher than in chronic HCV, chronic active hepatitis, and cirrhosis, and could be a marker for HCC diagnosis and a candidate gene for molecularly targeted therapy ( Zekri et al, 2013 ).…”

Section: The Role Of C-type Lectin Receptors In Cancersmentioning

confidence: 99%

Mycobiota and C-Type Lectin Receptors in Cancers: Know thy Neighbors

et al. 2022

View full text Add to dashboard Cite

Numerous studies have demonstrated the importance of gut bacteria in the development of malignancy, while relatively little research has been done on gut mycobiota. As a part of the gut microbiome, the percentage of gut mycobiota is negligible compared to gut bacteria. However, the effect of gut fungi on human health and disease is significant. This review systematically summarizes the research progress on mycobiota, especially gut fungi, in patients with head and neck cancer (HNC), esophageal cancer (EC), gastric cancer (GC), colorectal cancer (CRC), hepatocellular carcinoma (HCC), pancreatic cancer, melanoma, breast cancer, and lung carcinoma-induced cachexia. Moreover, we also describe, for the first time in detail, the role of the fungal recognition receptors, C-type lectin receptors (CLRs) (Dectin-1, Dectin-2, Dectin-3, and Mincle) and their downstream effector caspase recruitment domain-containing protein 9 (CARD9), in tumors to provide a reference for further research on intestinal fungi in the diagnosis and treatment of malignant tumors.

show abstract

Caspase recruitment domains. New potential markers for diagnosis of hepatocellular carcinoma associated with HCV in Egyptian patients

Cited by 10 publications

References 22 publications

Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma

Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma

CARD9 Signaling, Inflammation, and Diseases

Mycobiota and C-Type Lectin Receptors in Cancers: Know thy Neighbors

Contact Info

Product

Resources

About